查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1824450

2025年全球放射性藥物治療診斷學市場報告

Radiopharmaceutical Theranostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年放射性藥物治療診斷學市場規模將快速成長，到2029年將達到57.4億美元，複合年成長率為15.1%。預測期內的成長歸因於生物標記的發現和檢驗、基因組學和蛋白​​質組學技術、精準放射治療的發展、多學科合作以及患者權益的維護和支持。預測期內的主要趨勢包括倫理和法律考量、遠端醫療、以患者為中心的護理、放射性藥物的客製化以及奈米診療技術的發展。

未來五年15.1%的成長預測比我們先前的預測略有下降，下降了0.2%。這一下降主要源自於美國與其他國家之間關稅的影響。關稅上漲可能會增加美國患者的負擔，導致其從比利時和澳洲進口的鎦-177和鎵-68 PSMA套件的價格上漲，加劇核子醫學成本，並推遲個人化癌症治療。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，其影響也將更加廣泛。

隨著癌症發生率的不斷上升，放射性治療診斷學市場可望迎來成長。癌症的特徵是細胞異常生長、侵襲和擴散，需要有針對性的個人化治療方案才能有效治療。放射性藥物治療診斷學在癌症治療中發揮著至關重要的作用，能夠提供精準的個人化治療方案。美國癌症協會估計，光是在美國，2023年將新增190萬例癌症病例，約609,820人因此死亡。預計這些癌症診斷中的大多數（88%）年齡在50歲及以上。癌症發生率的上升是推動放射性藥物治療診斷學市場擴張的關鍵因素。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球放射性藥物治療診斷學：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球放射性藥物治療診斷學市場：成長率分析
  • 全球放射性藥物治療診斷學市場表現：規模與成長，2019-2024
  • 全球放射性藥物治療診斷學市場預測：規模與成長，2024-2029年，2034年
  • 全球放射性藥物治療治療診斷學：總目標市場（TAM）

第6章 市場細分

  • 全球放射性藥物治療診斷學市場（按產品類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • α發射體
  • BETA射線發射器
  • 正子斷層掃描（PET）示蹤劑
  • 全球放射性藥物治療診斷學市場（按來源、實際和預測），2019-2024 年、2024-2029 年、2034 年
  • 核子反應爐
  • 迴旋加速器
  • 全球放射性藥物治療診斷學市場：依放射性同位素、實際與預測，2019-2024 年、2024-2029 年、2034 年
  • Technetium-99
  • 鎵-68
  • 碘-131
  • 碘-123
  • 18樓
  • Y-90
  • 鎦（Lu）177
  • 銅（Cu）67
  • 銅（Cu）64
  • 其他放射內視鏡
  • 全球放射性藥物治療診斷學市場：依適應症、實際與預測，2019-2024 年、2024-2029 年、2034 年
  • 腫瘤學
  • 心臟病學
  • 神經病學
  • 其他適應症
  • 全球放射性藥物治療診斷學市場：按最終用戶、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 診斷影像中心
  • 學術研究機構
  • 其他最終用戶
  • 全球放射性藥物治療診斷學市場：依阿爾法發射體（產品類型）細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 錒-225
  • 鐳-223
  • 鉍 213
  • 其他α射線放射性藥物
  • 全球放射性藥物治療診斷學市場：依BETA發射體細分（依產品種類）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 碘-131
  • 鎦-177
  • 釔90
  • 其他BETA射線放射性藥物
  • 全球放射性藥物治療診斷學市場：正子斷層掃描 (PET) 示蹤劑細分市場（按產品類型、實際及預測），2019-2024 年、2024-2029 年、2034 年
  • 氟脫氧葡萄糖（FDG）
  • 鎵-68
  • 碳-11
  • 其他PET示踪劑

第7章 區域和國家分析

  • 全球放射性藥物治療診斷學市場：區域表現與預測（2019-2024 年、2024-2029 年及 2034 年）
  • 全球放射性藥物治療診斷學市場：國家、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 放射性藥物治療診斷學市場：競爭格局
  • 放射性藥物治療診斷學市場：公司簡介
    • Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • GE HealthCare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • China Grand Pharmaceutical & Healthcare. Overview, Products and Services, Strategy and Financial Analysis
    • Lantheus Medical Imaging Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Curium Pharma
  • Advanced Accelerator Applications
  • Telix Pharmaceuticals Ltd.
  • Bracco Imaging SpA
  • NTP Radioisotopes SOC Ltd.
  • Navidea Biopharmaceuticals Inc.
  • Jubilant DraxImage Inc.
  • NorthStar Medical Radioisotopes LLC
  • Blue Earth Diagnostics Ltd.
  • Precirix NV
  • SpectronRx
  • Viewpoint Molecular Targeting Inc.
  • NuView Life Sciences
  • Alpha-9 Theranostics Inc.
  • RadioMedix Inc

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年放射性藥物治療診斷學市場：提供新機會的國家
  • 2029 年放射性藥物治療診斷學市場：細分市場帶來新機會
  • 2029 年放射性藥物治療診斷學市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r25248u

Radiopharmaceutical theranostics involves a combined medical approach that integrates therapeutics (treatment) and diagnostics (diagnosis) through the utilization of radiopharmaceuticals. These substances are employed for patient diagnosis, therapy, and personalized management.

The primary product categories within radiopharmaceutical theranostics include alpha emitters, beta emitters, and positron emission tomography (PET) tracers. Alpha emitters are radioactive substances emitting alpha particles, characterized by high-energy particles consisting of two protons and two neutrons. Various sources for these include nuclear reactors and cyclotrons, and the diverse radioisotopes encompass technetium-99, gallium-68, iodine-131, iodine-123, 18F, Y-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, among others. These radiopharmaceuticals find applications in oncology, cardiology, neurology, and other medical indications, and are utilized by various end-users, including hospitals, diagnostic imaging centers, academic and research institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The radiopharmaceutical theranostics market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceutical theranostics market statistics, including radiopharmaceutical theranostics industry global market size, regional shares, competitors with a radiopharmaceutical theranostics market share, detailed radiopharmaceutical theranostics market segments, market trends, and opportunities, and any further data you may need to thrive in the radiopharmaceutical theranostics industry. This radiopharmaceutical theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radiopharmaceutical theranostics market size has grown rapidly in recent years. It will grow from $2.88 billion in 2024 to $3.27 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to radiopharmaceutical development, clinical research advances, investment in research, regulatory approval, and nuclear medicine progress.

The radiopharmaceutical theranostics market size is expected to see rapid growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to biomarker discovery and validation, genomic and proteomic technologies, precision radiotherapy development, interdisciplinary collaborations, patient advocacy and support. Major trends in the forecast period include ethical and legal considerations, telemedicine in theranostics, patient-centric care, radiopharmaceutical customization, and nano-theranostics development.

The forecast of 15.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of lutetium-177 and gallium-68 PSMA kits sourced from Belgium and Australia, exacerbating nuclear medicine expenses and delaying personalized cancer treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The radiopharmaceutical theranostics market is poised for growth, driven by the increasing incidence of cancer. Cancer, characterized by abnormal cell growth that can invade and spread, necessitates targeted and personalized approaches for effective treatment. Radiopharmaceutical theranostics plays a crucial role in cancer treatment, offering precision and personalized solutions. In the US alone, the American Cancer Society estimates that 1.9 million new cancer cases may be diagnosed in 2023, resulting in approximately 609,820 deaths. The majority of these diagnoses, 88%, are expected to be in individuals aged 50 and above. The rising prevalence of cancer is a key factor fueling the expansion of the radiopharmaceutical theranostics market.

Increasing healthcare expenditure is playing a significant role in the growth of the radiopharmaceutical theranostics market in the future. Supportive government initiatives, along with grants and funding for research and development in the area of radiopharmaceutical theranostics, promote innovation and facilitate the commercialization of new products. For example, in October 2024, the Centers for Medicare & Medicaid Services, a federal agency in the US, reported that prescription drug spending increased by 8.4%, reaching $405.9 billion in 2022, surpassing the 6.8% growth seen in 2021. Consequently, the rising healthcare expenditure is expected to propel the radiopharmaceutical theranostics market.

Leading companies in the radiopharmaceutical theranostics market are embracing a strategic partnership model to create innovative therapies. These collaborations allow radiopharmaceutical theranostics firms to pool resources and expertise, improve research and development capabilities, broaden market reach, and speed up commercialization, ultimately fostering innovation and growth within the industry. For example, in March 2023, Radiopharm Theranostics, a biotechnology company based in Australia, formed a partnership with Pharma15 Corporation, a US-based venture, to develop next-generation therapeutic radiopharmaceuticals aimed at prostate cancer. The focus is on overcoming resistance to current PSMA-targeted therapies while improving selectivity to reduce toxicity in healthy tissues.

Companies operating in the radiopharmaceutical theranostics market are also focusing on the development of theranostics for cancer treatment. Theranostic approaches aim to provide targeted therapies and diagnostic solutions for rare diseases, particularly for patients with limited treatment options such as cancer. In November 2023, GE HealthCare Technologies Inc. launched theranostic solutions for cancer, marking a significant stride in precision medicine. Theranostics utilizes therapeutic agents in conjunction with imaging technology to identify and target cancer cells for destruction.

In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company, acquired Pharma15 Corporation for $4 million. This strategic move positions Radiopharm to explore next-generation radiopharmaceuticals for prostate cancer treatment, surpassing PSMA-based therapies, and advancing innovative solutions for patients. Pharma15 Corporation, a US-based pharmaceutical company, specializes in radio-immuno-theranostics platforms and pharmaceutical products' development, aligning with Radiopharm's focus on advancing radiopharmaceutical products.

Major companies operating in the radiopharmaceutical theranostics market include Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.

North America was the largest region in the radiopharmaceutical theranostics market in 2024. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radiopharmaceutical theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radiopharmaceutical theranostics market includes revenues earned by providing genetic testing, targeted therapy services, contract development, and manufacturing services, consultation and interpretation, and personalized therapeutic interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiopharmaceutical Theranostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radiopharmaceutical theranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radiopharmaceutical theranostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radiopharmaceutical theranostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Alpha Emitters; Beta Emitters; Positron Emission Tomography (PET) Tracers
  • 2) By Source: Nuclear Reactors; Cyclotrons
  • 3) By Radioisotope: Technetium-99; Gallium-68; Iodine-131; Iodine-123; 18F; Y-90; Lutetium (Lu) 177; Copper (Cu) 67; Copper (Cu) 64; Other Radioscopes
  • 4) By Indication: Oncology; Cardiology; Neurology; Other Indications
  • 5) By End User: Hospitals; Diagnostic Imaging Centers; Academic And Research Institutes; Other End Users
  • Subsegments:
  • 1) By Alpha Emitters: Actinium-225; Radium-223; Bismuth-213; Other Alpha-Emitting Radiopharmaceuticals
  • 2) By Beta Emitters: Iodine-131; Lutetium-177; Yttrium-90; Other Beta-Emitting Radiopharmaceuticals
  • 3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG); Gallium-68; Carbon-11; Other PET Tracers
  • Companies Mentioned: Cardinal Health Inc.; GE HealthCare Technologies Inc.; Bayer AG; China Grand Pharmaceutical & Healthcare.; Lantheus Medical Imaging Inc.; Curium Pharma; Advanced Accelerator Applications; Telix Pharmaceuticals Ltd.; Bracco Imaging S.p.A; NTP Radioisotopes SOC Ltd.; Navidea Biopharmaceuticals Inc.; Jubilant DraxImage Inc.; NorthStar Medical Radioisotopes LLC; Blue Earth Diagnostics Ltd.; Precirix NV; SpectronRx; Viewpoint Molecular Targeting Inc.; NuView Life Sciences; Alpha-9 Theranostics Inc.; RadioMedix Inc; RayzeBio Inc; Fusion Pharmaceuticals Inc; Actinium Pharmaceuticals Inc.; Eckert & Ziegler Strahlen- und Medizintechnik AG; Ariceum Therapeutics GmbH; Radiopharm Theranostics Ltd; Ratio Therapeutics Inc; Primo Biotechnology; Bivision Biomedical Technology (Nanjing) Co. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Radiopharmaceutical Theranostics Market Characteristics

3. Radiopharmaceutical Theranostics Market Trends And Strategies

4. Radiopharmaceutical Theranostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Radiopharmaceutical Theranostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Radiopharmaceutical Theranostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Radiopharmaceutical Theranostics Market Growth Rate Analysis
  • 5.4. Global Radiopharmaceutical Theranostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Radiopharmaceutical Theranostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Radiopharmaceutical Theranostics Total Addressable Market (TAM)

6. Radiopharmaceutical Theranostics Market Segmentation

  • 6.1. Global Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpha Emitters
  • Beta Emitters
  • Positron Emission Tomography (PET) Tracers
  • 6.2. Global Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nuclear Reactors
  • Cyclotrons
  • 6.3. Global Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Technetium-99
  • Gallium-68
  • Iodine-131
  • Iodine-123
  • 18F
  • Y-90
  • Lutetium (Lu) 177
  • Copper (Cu) 67
  • Copper (Cu) 64
  • Other Radioscopes
  • 6.4. Global Radiopharmaceutical Theranostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Cardiology
  • Neurology
  • Other Indications
  • 6.5. Global Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Imaging Centers
  • Academic And Research Institutes
  • Other End Users
  • 6.6. Global Radiopharmaceutical Theranostics Market, Sub-Segmentation Of Alpha Emitters, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Actinium-225
  • Radium-223
  • Bismuth-213
  • Other Alpha-Emitting Radiopharmaceuticals
  • 6.7. Global Radiopharmaceutical Theranostics Market, Sub-Segmentation Of Beta Emitters, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Iodine-131
  • Lutetium-177
  • Yttrium-90
  • Other Beta-Emitting Radiopharmaceuticals
  • 6.8. Global Radiopharmaceutical Theranostics Market, Sub-Segmentation Of Positron Emission Tomography (PET) Tracers, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fluorodeoxyglucose (FDG)
  • Gallium-68
  • Carbon-11
  • Other PET Tracers

7. Radiopharmaceutical Theranostics Market Regional And Country Analysis

  • 7.1. Global Radiopharmaceutical Theranostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Radiopharmaceutical Theranostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Radiopharmaceutical Theranostics Market

  • 8.1. Asia-Pacific Radiopharmaceutical Theranostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Radiopharmaceutical Theranostics Market

  • 9.1. China Radiopharmaceutical Theranostics Market Overview
  • 9.2. China Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Radiopharmaceutical Theranostics Market

  • 10.1. India Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Radiopharmaceutical Theranostics Market

  • 11.1. Japan Radiopharmaceutical Theranostics Market Overview
  • 11.2. Japan Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Radiopharmaceutical Theranostics Market

  • 12.1. Australia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Radiopharmaceutical Theranostics Market

  • 13.1. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Radiopharmaceutical Theranostics Market

  • 14.1. South Korea Radiopharmaceutical Theranostics Market Overview
  • 14.2. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Radiopharmaceutical Theranostics Market

  • 15.1. Western Europe Radiopharmaceutical Theranostics Market Overview
  • 15.2. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Radiopharmaceutical Theranostics Market

  • 16.1. UK Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Radiopharmaceutical Theranostics Market

  • 17.1. Germany Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Radiopharmaceutical Theranostics Market

  • 18.1. France Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Radiopharmaceutical Theranostics Market

  • 19.1. Italy Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Radiopharmaceutical Theranostics Market

  • 20.1. Spain Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Radiopharmaceutical Theranostics Market

  • 21.1. Eastern Europe Radiopharmaceutical Theranostics Market Overview
  • 21.2. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Radiopharmaceutical Theranostics Market

  • 22.1. Russia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Radiopharmaceutical Theranostics Market

  • 23.1. North America Radiopharmaceutical Theranostics Market Overview
  • 23.2. North America Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Radiopharmaceutical Theranostics Market

  • 24.1. USA Radiopharmaceutical Theranostics Market Overview
  • 24.2. USA Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Radiopharmaceutical Theranostics Market

  • 25.1. Canada Radiopharmaceutical Theranostics Market Overview
  • 25.2. Canada Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Radiopharmaceutical Theranostics Market

  • 26.1. South America Radiopharmaceutical Theranostics Market Overview
  • 26.2. South America Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Radiopharmaceutical Theranostics Market

  • 27.1. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Radiopharmaceutical Theranostics Market

  • 28.1. Middle East Radiopharmaceutical Theranostics Market Overview
  • 28.2. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Radiopharmaceutical Theranostics Market

  • 29.1. Africa Radiopharmaceutical Theranostics Market Overview
  • 29.2. Africa Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Radiopharmaceutical Theranostics Market Competitive Landscape And Company Profiles

  • 30.1. Radiopharmaceutical Theranostics Market Competitive Landscape
  • 30.2. Radiopharmaceutical Theranostics Market Company Profiles
    • 30.2.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. GE HealthCare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. China Grand Pharmaceutical & Healthcare. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Lantheus Medical Imaging Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Radiopharmaceutical Theranostics Market Other Major And Innovative Companies

  • 31.1. Curium Pharma
  • 31.2. Advanced Accelerator Applications
  • 31.3. Telix Pharmaceuticals Ltd.
  • 31.4. Bracco Imaging S.p.A
  • 31.5. NTP Radioisotopes SOC Ltd.
  • 31.6. Navidea Biopharmaceuticals Inc.
  • 31.7. Jubilant DraxImage Inc.
  • 31.8. NorthStar Medical Radioisotopes LLC
  • 31.9. Blue Earth Diagnostics Ltd.
  • 31.10. Precirix NV
  • 31.11. SpectronRx
  • 31.12. Viewpoint Molecular Targeting Inc.
  • 31.13. NuView Life Sciences
  • 31.14. Alpha-9 Theranostics Inc.
  • 31.15. RadioMedix Inc

32. Global Radiopharmaceutical Theranostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radiopharmaceutical Theranostics Market

34. Recent Developments In The Radiopharmaceutical Theranostics Market

35. Radiopharmaceutical Theranostics Market High Potential Countries, Segments and Strategies

  • 35.1 Radiopharmaceutical Theranostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Radiopharmaceutical Theranostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Radiopharmaceutical Theranostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer